Acta Paediatrica · 1997 · 50 citations · 1 references
MedicineEndocrinologyPediatricsHuman NutritionNeuroendocrinologyPediatric EndocrinologyChild GrowthGrowth AssessmentGrowth DisordersGrowth HormoneGrowth Hormone TherapyPediatric GrowthBody Composition MeasurementBody Fat PercentageCross-sectional Muscle AreaHormonal Regulation Of GrowthInsulin-like Growth Factor 1 DeficiencyInsulin-like Growth Factor DeficiencyMuscle Fiber Cross-sectional AreaPrader-willi Syndrome Treatment
A controlled, randomized study was conducted to assess the effect of growth hormone (GH) treatment on growth, body composition and behaviour in prepubertal children (3-12 years of age) with Prader-Willi syndrome. GH treatment was given to one group of 15 patients (group A) at a dose of 0.1 IU/kg/day for 2 years. The second group (group B; n = 12) was not treated for the first year and was then given GH at a dose of 0.2 IU/kg/day for the second year. All patients had low 24-hour levels of GH and insulin-like growth factor I before GH treatment. Height velocity SDS increased from -1.9 +/- 2.0 to 6.0 +/- 3.2 during the first year of GH treatment in group A, and from -1.4 +/- 1.2 to 10.1 +/- 3.9 in the second year of the study in group B. When GH treatment was stopped, height velocity declined dramatically. Height SDS followed a similar pattern. GH treatment reduced the percentage body fat and increased the muscle area of the thigh. Isometric muscle strength was also increased. In addition, GH treatment appeared to have psychological and behavioural benefits, which were reversed after cessation of treatment. It was concluded that GH treatment improves growth, body composition and behaviour in children with Prader-Willi syndrome.
1
Prader-Willi Syndrome: Consensus Diagnostic Criteria
Vanja A. Holm, Suzanne B. Cassidy, Merlin G. Butler et al. · PEDIATRICS · 1993 · 1.3K citations · Full text